San Francisco Bay Area Chapter In Person Event: Regulatory Success Strategies for Emerging Therapeutic Companies

Lynne Krummen

Executive Vice President, Product Development, LARK Biotech Consulting, LLC

Lynne Krummen, Ph.D., LARK Biotech Consulting, LLC, is currently an independent consultant in the areas of biotechnology Product Development, CMC Regulatory and Technical Development. From 2018 through May 2024, she has served at various roles at Vir Biotechnology, including its Executive Vice President, Product Development and Senior Vice President of Regulatory since October 2023. She joined Vir in 2018. During her time at Vir, she has focused on ensuring the timely progress of our critical clinical pipeline programs, including the accelerated Emergency Authorization of sotrovimab for treating individuals at high risk of severe complications from COVID- 19.

Before joining Vir, Dr. Krummen held a variety of leadership positions of increasing responsibility at Genentech, Inc., most recently as Vice President of Technical Development from 2016-2018. Prior to that, she was Vice President and Roche Global Head of Biologics, Regulatory Chemistry, Manufacturing and Controls (CMC). Before that, she held various leadership positions at Genentech, Inc. in Product Development, CMC Regulatory, Process Development Operations and Cell Culture Development.

Dr. Krummen received her Ph.D. in Endocrinology from the University of Cincinnati College of Medicine.

: lynne-krummen-b52b984

Reem Mahrat

Founder and CEO, EazeBio

Reem Mahrat is a visionary serial entrepreneur and a respected leader in clinical research, biotechnology, and precision diagnostics.  With a foundation in chemical engineering, she has spent over two decades launching and scaling ventures at the intersection of chemistry,  biology, and artificial intelligence—propelling major advancements in next-generation diagnostics and personalized medicine.

Reem has made significant contributions to antibody development for both therapeutic and diagnostic applications, expertly guiding candidates  from preclinical discovery through clinical development. Her unique blend of scientific rigor and business acumen empowers her to drive  innovation and success across the biopharmaceutical landscape.

Her career is defined by transformative leadership roles. Reem has served as an advisor at Daybreak Labs and founded, led, and exited  several breakthrough companies—including RamanID and Calico Bio Labs. She also co-founded Verano Bioscience and currently leads research  innovation at Precision Biopharma. She is the Founder and CEO of EazeBio, a precision wellness company focused on early detection of metabolic  and autoimmune stress, and reclaiming agency in women’s health. Reem also serves as Entrepreneur-in-Residence (EIR), lending her expertise  to support innovation-driven biotech ventures.

 A passionate advocate for precision medicine, Reem is an active member of leading research and advocacy organizations including AACR, ASCO,  SITC, and HBA, and serves as a chapter leader for Together Women Rise, supporting global women’s empowerment.  Reem’s mission is deeply personal. As someone living with an autoimmune condition, she openly shares her health journey to break stigma, create connection, and inspire others navigating similar challenges.  “Sharing my story helps create a sense of community, educates others on the realities of living with autoimmunity, and offers comfort to those  feeling isolated or misunderstood. Through this sharing, I find empowerment and connection.”

Her leadership blends scientific innovation with radical empathy, setting a new standard for biotech founders—one where personal experience fuels purpose, and data meets compassion.

: reem-m

Barbara Troupin

Fractional Chief Medical and Strategy Officer

Barbara Troupin is a fractional Chief Medical Officer working for several early-stage biotech, therapeutics and digital health companies. She works to guide teams on portfolio strategy, clinical development, regulatory planning and engagement, fundraising, and company growth. She also sits as an Independent Director on the Board of Equillium Bio (NASDAQ: EQ), and ProSciento, a private-equity backed CRO. Over her 20+ years as a life science executive, her roles have spanned Clinical, Medical, Regulatory, Operations and Strategy functional areas, working in both private and public companies. She holds an MD from the University of Pennsylvania and an MBA from the Wharton School of Business. She is broadly curious; an avid connector and values relationships where mutual learning and growth occur.

: btroupin

Kevin Tate

B2B SaaS Revenue Leader, Startup & Scale-Up, Founder & Investor, Kivo

Kevin is a seasoned Go‑to‑Market executive with 25 years of Marketing and Sales leadership experience, known for building and scaling high‑performing teams across emerging technology sectors. His marketing background spans Product, Corporate, and Demand Generation Marketing, leading global initiatives across industries and geographies.

He has spent much of his career supporting growth‑stage companies in dynamic markets including eCommerce, Enterprise SaaS, Social Media/Web 2.0, IoT, and Martech. Kevin also brings significant M&A experience, serving as a key contributor to diligence, acquisition, and post‑integration efforts across three successful transactions.

A frequent event speaker, podcast guest, and article contributor, Kevin remains an avid technologist at heart—beginning his career as a UNIX and database programmer in 1996 and carrying that technical curiosity into every leadership role since.

: kevin-tate

Jenny Chaplin

Fractional Chief Medical and Strategy Officer

Jenny Chaplin is an accomplished, results-driven, and versatile drug development professional, with a strong track record of organizational excellence and translating strategy into execution. She has delivered multiple projects on target, managed challenging global alliances, and successfully taken on diverse functional leadership roles, including Program Management, HR, and Clinical Operations. Jenny’s experience spans large pharma to smaller, early-stage biotech and she is adept at wearing multiple hats and navigating dynamic environments. She is currently the Principal of Saffyre Consulting. Most recently,she was Vice President, Strategic Operations, at Bellicum Pharmaceuticals, where she built up Program Management as a function. She previously held project management roles at Pfizer and Vical, Inc. after transitioning from an early career in research.

: jenny-chaplin

Tuan Nguyen

Chief Financial Officer, Arbutus Biopharma Corporation

As the Chief Financial Officer, Tuan leads the financial operations and strategy of a biopharmaceutical company that develops innovative therapies for unmet medical needs. Tuan has over 20 years of experience in finance, business development, and investment consulting, with a focus on the life sciences sector.

Tuan  have a proven track record of partnering finance with business objectives to drive continuous revenue, profit, and market-share growth. Tuan has a keen ability to assess complex transactions, perform financial and data modeling, and conduct valuation and economic analysis. Tuan holds a top 20 MBA with dual concentrations in Finance and Organization & Management, and is fluent in Vietnamese. Tuan is passionate about creating value for patients, shareholders, and stakeholders through strategic financial planning and execution.

: tuanvnguyen